Related Experiment Video
Updated: May 9, 2026
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
Adaptive deep brain stimulation in advanced Parkinson disease
Simon Little1, Alex Pogosyan, Spencer Neal
1Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford.
Annals of Neurology
|July 16, 2013
Summary
Brain-computer interfaces (BCIs) offer a new way to control deep brain stimulation (DBS) for Parkinson disease (PD). This adaptive DBS (aDBS) improved motor function and reduced stimulation time compared to conventional methods.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Neuromodulation
Background:
- Brain-computer interfaces (BCIs) show potential for modulating pathological brain activity.
- Parkinson disease (PD) is a neurodegenerative disorder affecting motor control.
- Deep brain stimulation (DBS) is a common treatment for advanced PD, but continuous stimulation has limitations.
Purpose of the Study:
- To demonstrate the proof-of-principle of using a BCI to control DBS in PD patients.
- To investigate if personalized, real-time stimulation can improve efficacy and efficiency over conventional DBS.
- To compare BCI-controlled adaptive DBS (aDBS) with continuous DBS (cDBS), no stimulation, and random intermittent stimulation.
Main Methods:
- BCI-controlled adaptive DBS (aDBS) was tested in 8 PD patients targeting the subthalamic nucleus.
- Local field potentials from stimulation electrodes provided feedback for real-time stimulation adjustments.
- Motor function was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) in blinded and unblinded evaluations.
Main Results:
- aDBS resulted in significant motor score improvements: 66% (unblinded) and 50% (blinded).
- These improvements were superior to cDBS by 29% (unblinded) and 27% (blinded).
- aDBS reduced stimulation time by 56% and energy requirements significantly compared to cDBS.
Conclusions:
- BCI-controlled DBS is a feasible approach for treating Parkinson disease.
- Adaptive DBS offers enhanced efficacy and efficiency compared to conventional continuous DBS.
- This technology holds promise for personalized neuromodulation in neurological disorders.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...